Wednesday, May 18, 2011
PSA Test Could Be Improved to Spot Prostate Cancer (HealthDay)
(HealthDay):
"HealthDay - MONDAY, May 16 (HealthDay News) --
Amid the controversy swirling around the value of PSA testing as a screen for prostate cancer, new evidence emerges that there may be ways to fine-tune the screening so it benefits more men, while avoiding unnecessary biopsies and treatment."
According to news conference moderator Dr. Christopher Amling, chief of urology at Oregon Health & Science University in Portland, the AUA modified its prostate cancer screening guidelines in 2009 to recommend that men should start screening at age 40, or age 45 at the latest.
New Drug Extends Life a Bit in Advanced Prostate Cancer (HealthDay)
(HealthDay):
"HealthDay - MONDAY, May 16 (HealthDay News) --
For men with advanced hormone-resistant prostate cancer who have also failed chemotherapy, the new drug Zytiga (abiraterone acetate) along with the steroid prednisone appears to increase survival modestly, a new study reports."
Men taking the drug combination had an average survival of 14.8 months, compared with 10.9 months for men taking a placebo.
"This study tells us that there is a form of hormonal therapy, abiraterone, that works in people who had standard hormonal therapy and chemotherapy," said prostate cancer expert Dr. Anthony D'Amico, chief of genitourinary radiation oncology at Brigham and Women's Hospital in Boston.
"It will provide people with late-stage disease with an opportunity for an extended survival that they didn't have before. I can't say it's a home run because it's only a few months improvement," he added.
Tuesday, May 17, 2011
Smoking Might Raise Odds for Prostate Cancer's Return (HealthDay)
(HealthDay):
"HealthDay - MONDAY, May 16 (HealthDay News) --
In men who've had their prostate surgically removed due to prostate cancer, smoking seems linked to a rise in blood levels of prostate specific antigen (PSA) -- a measure
of the risk of cancer recurrence."
"These data indicate that smoking history could provide valuable insight and should be included in risk-assessment models for prostate cancer," study presenter Dr. Joseph C. Presti said in an AUA news release.
"The study also presents a strong message to men: quitting smoking now could impact your ability to survive prostate cancer later," he added.
Monday, May 16, 2011
Poor Sleep Tied to Incontinence, Impotence (HealthDay)
(HealthDay): "HealthDay - SATURDAY, May 14 (HealthDay News) -- Sleep problems are
associated with erectile dysfunction and urologic conditions such as
incontinence, according to the results of two new studies."
"We know that proper amounts of sleep and quality of sleep can impact a wide range of health conditions, including erectile function and lower urinary tract symptoms," AUA spokesman Dr. Kevin T. McVary said in an association news release. "These data may help us better assess how helping patients modify their sleep patterns may help improve their health and overall quality of life."
Because these studies were presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.
Saturday, May 7, 2011
Surgery better for younger prostate patients: report (AFP)
(AFP): "
AFP - Surgery appears to be a better treatment option for early prostate cancer than 'watchful waiting,' particularly for younger patients, according to a Swedish study.
"
Thursday, May 5, 2011
Aggressive Treatment May Be Beneficial for Early Prostate Cancer (HealthDay)
Cancer
(HealthDay): "HealthDay - WEDNESDAY, May 4 (HealthDay News) -- Among men under 65 with
early stage prostate cancer, those who have the prostate gland removed are
less likely to die than those who adopt a 'watchful waiting' approach,
according to a new long-term study out of Europe."
Men with prostate cancer face a confusing maze of options today, including not only surgery but hormone therapy, different kinds of radiation therapy and even simply foregoing medical treatment while monitoring the cancer closely ("watchful waiting," also known as "active surveillance").
"Watchful waiting" is often recommended when a man is not expected to die of the cancer and would like to avoid the risk of the debilitating side effects associated with prostate cancer treatment. These may include: incontinence and erectile dysfunction (surgery); erectile dysfunction and secondary cancers (radiation therapy); nausea, breast growth, liver problems (hormonal therapy); and weakness, hair loss, fluid retention (chemotherapy).
Supplements don't prevent prostate cancer: study
Canadian researchers found that vitamin E, selenium and soy, taken daily for three years, provided no benefit to men who were at a higher risk of developing the disease.
The findings come three years after a larger study of men, who were at no increased risk of prostate cancer, also found no benefit of selenium or vitamin E supplementation (see Reuters Health report, October 28, 2008).